Primary Intestinal Malignant Melanoma

TANJU ACAR
RAMAZAN TAÇYILDIZ
ŞEVKİ KARAKAYALI
HALDUN VAHAPOĞLU
RACİ AYDIN

Follow this and additional works at: https://journals.tubitak.gov.tr/medical

Part of the Medical Sciences Commons

Recommended Citation
ACAR, TANJU; TAÇYILDIZ, RAMAZAN; KARAKAYALI, ŞEVKİ; VAHAPOĞLU, HALDUN; and AYDIN, RACİ (2002) "Primary Intestinal Malignant Melanoma," Turkish Journal of Medical Sciences: Vol. 32: No. 2, Article 18. Available at: https://journals.tubitak.gov.tr/medical/vol32/iss2/18

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
The patient, a 58-year-old woman underwent an exploratory laparotomy for an obstructing acute intussusception in July 1992. She was found upon exploration to have a 3.0 by 2.0 cm tumor in the distal jejunum causing partial obstruction of the proximal small bowel and resection of the jejunum was done with end-to-end anastomosis. On the fixed specimen, the tumor was 3.5 cm in diameter with a 3.0 cm proximal and 6.0 cm distal margin. Frozen and permanent sections showed malignant melanoma (Fig. 1,2). The mesenteric lymph nodes revealed reactive lymphadenitis without evidence of metastases. No primary lesion was found on repeat thorough physical examination. Postoperatively, the patient underwent fundoscopic examination, colposcopy, and flexible sigmoidoscopy to 65 cm, but no other primary site could be found. The patient’s recovery was uneventful, with no evidence of infection. She was discharged 10 days postoperatively. Her final diagnosis was primary malignant melanoma of the small intestine. After discussing all of the possible standard and investigational systemic adjuvant therapies for malignant melanoma, the patient declined further treatment. Repeated clinical examinations, serum immunoglobulins, chest radiograph, bone scan, and computed tomography (CT) scans of the abdomen and brain were all normal. A laparotomy was performed in May 2000 because of an incisional hernia. There was no sign of the disease in her abdomen. She is still without any evidence of the illness 9 years after diagnosis.

Most cases of malignant melanoma of the GI tract are secondary to metastases (1). According to Reemst, less than 5% of the patients present with symptoms that are often nonspecific and late. The most common symptoms are acute gastrointestinal bleeding and anemia (2). The areas of the GI tract that can be involved and their frequencies are as follows: small bowel (58-71%), stomach (20-27%), colon (22%), esophagus (5%), and rectum (2%) (3). There have been very rare case reports of GI tract malignant melanomas without any other known primary site. In Elsayed’s retrospective study, he reviewed 103 cases of malignant melanoma in the small intestine (77 surgical resections, 26 autopsies) accessioned at the Pathology Department between 1945 and 1991. In 46% of cases (47 patient), there was no record of a primary lesion preceding the intestinal tumor and 23% of these were autopsies (4). Ollila reported that GI tract involvement was diagnosed premortem in only 4% of patients (5). In approximately 60% of patients who die from melanoma, the autopsy reveals metastases in the GI tract (6). Because the small and large intestines normally contain no melanoblasts, some authors believe that primary malignant melanomas of the GI tract are unlikely (7). However, melanocytes have been found in the alimentary tract as well as the respiratory tract even in lymph nodes. Another hypothesis supporting a primary etiology proposes that malignant melanomas can originate from neural crest cells (8). These multi-potential cells become amine precursor uptake and decarboxylation (APUD) cells. APUD cells can undergo neoplastic transformation and produce tumors such as carcinoid, gastrinoma, and medullary thyroid carcinoma. Melanomas may originate from APUD cells, although...
unlike the usual ‘APUDomas’, malignant melanomas are not hormone producers.

Systemic adjuvant therapy for metastatic malignant melanoma is limited. There is no standard, effective chemotherapy after either palliative or curative resection of malignant melanoma of the GI tract. Investigational adjuvant therapy protocols include alpha interferon, interleukin, various chemotherapeutic drug combinations, active immunotherapy by vaccination with modified melanoma cells, and high-dose chemotherapy with autologous bone marrow transplants (9). At present, the prognosis for patients with untreated metastatic malignant melanoma remains poor. However, as demonstrated by our case and other reports, primary malignant melanoma of the GI tract may exist, and long-term survival may be accomplished with close follow-up and prompt surgical treatment.

Correspondence author:
Tanju ACAR
Söğütözü Sitesi, Akasya Apt. No: 8
Söğütözü, Ankara - TURKEY

References